Press releases
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
- Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
- Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
- Innate Pharma Reports Full Year 2023 Financial Results and Business Update
- Innate Pharma Announces Its Participation to Upcoming Investor Conference
- Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
- Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
- Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 80.86m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 178.30m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼